Wang, J., Yu, H., Hu, Z., Wu, Z., Ning, F., Yao, Y., Yu, G., Kong, J., Zhang, X., He, Z. (2026). Firmonertinib combined with platinum-based chemotherapy in patients with
                    <i>EGFR</i>
                    -mutant advanced NSCLC following disease progression on first-line third-generation EGFR-TKI.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8610